Abstract 113P
Background
Molecular differences between genetic ancestries in patients (pts) with bilary tract cancers (BTCs) and how they affect prognosis and treatment response are largely unknown. Compounding this problem is clinical trial enrollment for racial minorities with BTCs have been historically low, making it difficult to assess differences in treatment response between genetic ancestries. Our prior data indicated significant variation in somatic cancer genes between Caucasian and Asian pts. However, variations in African ancestry (AA) pts have not been described.
Methods
12,932 cases of BTCs of AA and European ancestries (EA) were reviewed from 3 databases (Foundation Medicine (n=10,849), MD Anderson Cancer Center (n=167) and AACR Genie (n=1,916). BTCs were divided into intrahepatic (ICC) and extrahepatic (ECC) cholangiocarcinomas and gallbladder cancers (GBC). Prevalence of alterations in 30 genes between genetic ancestries were compared using Fischer’s exact test on the Foundation Medicine database. P-values were corrected for false discovery rate using the Benjamini/Hochberg adjustment.
Results
We identified key clinical and genomic differences between AA and EA BTC cases in all 3 databases. The mean age of AA pts at diagnosis was earlier (62.3 years) compared to EA pts (65.1 years) (p<0.05). There was a higher percent of female AA BTC cases (63.2%) compared to female EA BTC cases (52.4%) (p<0.05). AA BTC cases had a statistically significant higher prevalence of TP53 (55.1% vs 39.7%) and TERT (10.0% vs 5.4%) alterations (p<0.001) compared to EA BTC cases. AA BTC cases also had a statistically significant higher prevalence of STK11, CCNE, ERBB2, and ARID2 alterations (p<0.05), and lower prevalence of IDH1, ARID1A, BAP1, BRAF, and PBRM1 alterations (p<0.05) compared to EA BTC cases. AA ICC cases had a statistically significant higher prevalence of FGFR2 (16.8% vs 11.7%) alterations (p<0.001) compared to EA ICC cases.
Conclusions
Our results highlight significant differences in genomic profiles among BTC cases of different genetic ancestries and support further research in how these differences contribute to prognosis and treatment response to targeted therapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D.C. Pavlick: Financial Interests, Personal, Full or part-time Employment: Foundation Medicine. J.S. Ross: Financial Interests, Personal, Full or part-time Employment, Medical Director: Foundation Medicine; Financial Interests, Personal, Stocks/Shares: Roche Holdings, Tango Therapeutics, Celsius Therapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
107P - Comprehensive genomic profiling of “The German-registry of incidental gallbladder carcinoma” cases
Presenter: Nihat Bugra Agaoglu
Session: Poster session 17
108P - FGFR2 fusions and their impact on efficacy of standard chemotherapy in patients with biliary tract cancer
Presenter: Binbin Zheng-Lin
Session: Poster session 17
109P - DNA damage repair pathways in biliary tract cancer: A new target for precision medicine?
Presenter: Ilektra Mavroeidi
Session: Poster session 17
110P - Detection of HER2 overexpression in biliary tract cancers: Comparison of AmoyDx® HER-2 (29D8) assay with ventana PATHWAY anti-HER-2/neu (4B5) assay
Presenter: Hui Dong
Session: Poster session 17
111P - The concordance between circulating tumor DNA and tissue genomic profiling in patients with advanced biliary tract cancer
Presenter: Seonjeong Woo
Session: Poster session 17
112P - Clinical, genomic and transcriptomic characteristics of young-onset biliary tract cancers
Presenter: Thomas Pudlarz
Session: Poster session 17
114P - Prospective longitudinal tumor-informed ctDNA in resectable biliary tract cancers
Presenter: Gentry King
Session: Poster session 17
115P - Inhibition of KLF5 reduces tumor growth and sensitizes to chemotherapy-induced cell death in experimental models of cholangiocarcinoma
Presenter: Ana Landa Magdalena
Session: Poster session 17
116P - Circulating tumour DNA- based minimal residual disease detection for biliary tract cancer
Presenter: Zhishuai Li
Session: Poster session 17